BACKGROUND: In patients with acute myocardial infarction (AMI), the number of transplanted autologous bone-marrow cells (BMC) has been linked to improvement in left ventricular ejection fraction (LVEF). Complete obstruction of myocardial microvasculature is indicated by microvascular obstruction (MO) in cardiac magnetic resonance imaging (CMR). We analyzed whether the number of transplanted cells and presence of MO were associated with improved LVEF in the double-blind, placebo-controlled, randomized intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. METHODS AND RESULTS: Patients (N = 42) received study therapy mean 7 days after AMI. Median number of transplanted BMC was 324 × 10(6). CMR was performed prior to study therapy and annually up to 3 years and revealed no difference between BMC and placebo population. Patients treated with a cell number above the median experienced a significant improvement in LVEF compared with patients with cell number below the median 3.6 ± 3.4 versus -0.5 ± 6.4 % (difference 4.1, 95 % CI 0.2 to 8.1 %, p = 0.04) at 6 months. The difference in LVEF change between the groups remained with 3.8 % (p = 0.12) at 12 months, 4.5 % (p = 0.07) at 24 months and 5.6 % (p = 0.03) at 36 months. BMC treated patients without MO experienced a better improvement in LVEF compared with patients with MO at 6, 12, 24 and 36 months with 3.5, 5.3, 6.4 and 3.2 %. CONCLUSIONS: In the randomized, placebo-controlled double-blind SCAMI trial improvement in LVEF up to 3 years was higher in BMC patients treated with a high cell number or without MO.
RCT Entities:
BACKGROUND: In patients with acute myocardial infarction (AMI), the number of transplanted autologous bone-marrow cells (BMC) has been linked to improvement in left ventricular ejection fraction (LVEF). Complete obstruction of myocardial microvasculature is indicated by microvascular obstruction (MO) in cardiac magnetic resonance imaging (CMR). We analyzed whether the number of transplanted cells and presence of MO were associated with improved LVEF in the double-blind, placebo-controlled, randomized intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. METHODS AND RESULTS:Patients (N = 42) received study therapy mean 7 days after AMI. Median number of transplanted BMC was 324 × 10(6). CMR was performed prior to study therapy and annually up to 3 years and revealed no difference between BMC and placebo population. Patients treated with a cell number above the median experienced a significant improvement in LVEF compared with patients with cell number below the median 3.6 ± 3.4 versus -0.5 ± 6.4 % (difference 4.1, 95 % CI 0.2 to 8.1 %, p = 0.04) at 6 months. The difference in LVEF change between the groups remained with 3.8 % (p = 0.12) at 12 months, 4.5 % (p = 0.07) at 24 months and 5.6 % (p = 0.03) at 36 months. BMC treated patients without MO experienced a better improvement in LVEF compared with patients with MO at 6, 12, 24 and 36 months with 3.5, 5.3, 6.4 and 3.2 %. CONCLUSIONS: In the randomized, placebo-controlled double-blind SCAMI trial improvement in LVEF up to 3 years was higher in BMC patients treated with a high cell number or without MO.
Authors: David M Clifford; Sheila A Fisher; Susan J Brunskill; Carolyn Doree; Anthony Mathur; Suzanne Watt; Enca Martin-Rendon Journal: Cochrane Database Syst Rev Date: 2012-02-15
Authors: Jaroslav Meluzín; Jirí Mayer; Ladislav Groch; Stanislav Janousek; Ivan Hornácek; Ota Hlinomaz; Petr Kala; Roman Panovský; Jirí Prásek; Milan Kamínek; Jaroslav Stanícek; Martin Klabusay; Zdenik Korístek; Milan Navrátil; Ladislav Dusek; Jaroslava Vinklárková Journal: Am Heart J Date: 2006-11 Impact factor: 4.749
Authors: Raj R Makkar; Rachel R Smith; Ke Cheng; Konstantinos Malliaras; Louise Ej Thomson; Daniel Berman; Lawrence Sc Czer; Linda Marbán; Adam Mendizabal; Peter V Johnston; Stuart D Russell; Karl H Schuleri; Albert C Lardo; Gary Gerstenblith; Eduardo Marbán Journal: Lancet Date: 2012-02-14 Impact factor: 79.321
Authors: Peter Bernhardt; Christoph Rodewald; Julia Seeger; Birgid Gonska; Dominik Buckert; Michael Radermacher; Vinzenz Hombach; Wolfgang Rottbauer; Jochen Wöhrle Journal: Clin Res Cardiol Date: 2015-09-22 Impact factor: 5.460
Authors: Johannes H Riffel; Marius G P Keller; Matthias Aurich; Yannick Sander; Florian Andre; Sorin Giusca; Fabian Aus dem Siepen; Sebastian Seitz; Christian Galuschky; Grigorios Korosoglou; Derliz Mereles; Hugo A Katus; Sebastian J Buss Journal: Clin Res Cardiol Date: 2015-02-03 Impact factor: 5.460
Authors: Muhammad R Afzal; Anweshan Samanta; Zubair I Shah; Vinodh Jeevanantham; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn Journal: Circ Res Date: 2015-07-09 Impact factor: 17.367
Authors: Gianluca Pontone; Patrizia Carità; Mark G Rabbat; Marco Guglielmo; Andrea Baggiano; Giuseppe Muscogiuri; Andrea I Guaricci Journal: Curr Cardiol Rep Date: 2017-08-31 Impact factor: 2.931
Authors: Marek Malecki; Emily Putzer; Chelsea Sabo; Afsoon Foorohar; Carol Quach; Chris Stampe; Michael Beauchaine; Raf Malecki; Xenia Tombokan; Mark Anderson Journal: Mol Cell Ther Date: 2014-05-01